A Randomized, Double-blind, Parallel Group, Multicenter Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of SAIT101 Versus MabThera Versus Rituxan in Patients With Rheumatoid Arthritis (RA)
Latest Information Update: 20 Jan 2022
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Acronyms RAMO-1
- Sponsors Archigen Biotech
- 05 Dec 2018 Status changed from recruiting to completed.
- 26 Dec 2017 Planned End Date changed from 1 Oct 2018 to 1 Dec 2019.
- 09 Aug 2017 Planned End Date changed from 1 Jun 2018 to 1 Oct 2018.